Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.

Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance

Open access
Leite, Luís Felipe, Noronha, Mariana Macambira, de Menezes, Junior Samuel Alonso, da Conceição, Lucas Diniz, Almeida, Luiz F. Costa, Cappellaro, Anelise Poluboiarinov, Belotto, Marcos, Biachi de Castria, Tiago, Peixoto, Renata D’Alpino, Megid, Thais Baccili Cury · 2025 · Cancers

Abstract

Epidermal growth factor receptor (EGFR) inhibitors remain a cornerstone in the treatment of metastatic colorectal cancer with RAS and BRAF wild-type cancer. Yet, primary and acquired resistance limit their benefit for many patients. A growing body of evidence reveals that resistance is not random but rather driven by a complex network of molecular alterations that sustain tumor growth independent of EGFR signaling. These include amplification of ERBB2 (HER2) and MET, activation of the PI3K and AKT pathways, EGFR extracellular domain mutations, and rare kinase fusions. The concept of negative hyperselection has emerged as a powerful strategy to refine patient selection by excluding tumors with these resistance drivers. Multiple clinical trials have consistently shown that patients who are hyperselected based on comprehensive molecular profiling achieve significantly higher response rates and improved survival compared to those selected by RAS and BRAF status alone. Liquid biopsy through circulating tumor DNA has further transformed this landscape, offering a noninvasive tool to capture tumor heterogeneity, monitor clonal evolution in real time, and guide rechallenge strategies after resistance emerges. Together, negative hyperselection, ctDNA-guided monitoring, and emerging therapeutics define a precision-oncology framework for identifying, tracking, and overcoming resistance to anti-EGFR therapy in mCRC, moving the field toward more effective and individualized care. Looking ahead, the development of innovative therapeutics such as bispecific antibodies, antibody drug conjugates, and RNA-based therapies promises to further expand in this challenging clinical scenario. These advances move precision oncology in colorectal cancer from concept to clinical reality, reshaping the standard of care through molecular insights.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers17172804

Cites

167 of 167 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Mechanisms of primary resistance to anti-EGFR therapy in metastatic colorectal cancer. Several genetic alterations drive intrinsic resistance to EGFR-targeted monoclonal antibodies such as cetuximab and panitumumab. These include activating mutations in KRAS and BRAF, amplification or mutation of HER2 and MET, extracellular domain mutations in EGFR, and alterations in downstream signaling components such as PIK3CA, AKT1, MEK1, and PTEN. These molecular events activate parallel or downstream signaling cascades, including the RAS RAF MEK ERK and PI3K AKT mTOR pathways, which sustain tumor cell survival, proliferation, and disease progression independent of EGFR signaling blockade.
Figure 1 Mechanisms of primary resistance to anti-EGFR therapy in metastatic colorectal cancer. Several genetic alterations drive intrinsic resistance to EGFR-targeted monoclonal antibodies such as cetuximab and panitumumab. These include activating mutations in KRAS and BRAF, amplification or mutation of HER2 and MET, extracellular domain mutations in EGFR, and alterations in downstream signaling components such as PIK3CA, AKT1, MEK1, and PTEN. These molecular events activate parallel or downstream signaling cascades, including the RAS RAF MEK ERK and PI3K AKT mTOR pathways, which sustain tumor cell survival, proliferation, and disease progression independent of EGFR signaling blockade.CC BY · PubMed Central
Figure 2 Mechanisms of Acquired Resistance to Anti-EGFR Therapy in Metastatic Colorectal Cancer. EGFR-targeted monoclonal antibodies (cetuximab or panitumumab) initially reduce tumor burden in RAS/BRAF wild-type colorectal cancer. However, under treatment pressure, resistant clones (e.g., with KRAS mutations) are positively selected or newly emerge through acquired mutations. These resistant subclones expand over subsequent treatment cycles, ultimately leading to disease progression despite continued anti-EGFR therapy.
Figure 2 Mechanisms of Acquired Resistance to Anti-EGFR Therapy in Metastatic Colorectal Cancer. EGFR-targeted monoclonal antibodies (cetuximab or panitumumab) initially reduce tumor burden in RAS/BRAF wild-type colorectal cancer. However, under treatment pressure, resistant clones (e.g., with KRAS mutations) are positively selected or newly emerge through acquired mutations. These resistant subclones expand over subsequent treatment cycles, ultimately leading to disease progression despite continued anti-EGFR therapy.CC BY · PubMed Central
Figure 3 Precision Oncology Framework for Anti-EGFR Therapy in Metastatic Colorectal Cancer. Liquid biopsy enables noninvasive, real-time molecular profiling across the treatment course. At baseline, panels assessing RAS/BRAF status and additional negative hyperselection markers (e.g., HER2, MET, MAP2K1, PIK3CA, PTEN, gene fusions) identify patients most likely to benefit from EGFR blockade. During treatment and at disease progression, serial ctDNA analysis detects acquired resistance mechanisms, supporting rechallenge decisions or the addition of targeted agents. This dynamic strategy integrates predictive and adaptive molecular insights to optimize anti-EGFR therapy.
Figure 3 Precision Oncology Framework for Anti-EGFR Therapy in Metastatic Colorectal Cancer. Liquid biopsy enables noninvasive, real-time molecular profiling across the treatment course. At baseline, panels assessing RAS/BRAF status and additional negative hyperselection markers (e.g., HER2, MET, MAP2K1, PIK3CA, PTEN, gene fusions) identify patients most likely to benefit from EGFR blockade. During treatment and at disease progression, serial ctDNA analysis detects acquired resistance mechanisms, supporting rechallenge decisions or the addition of targeted agents. This dynamic strategy integrates predictive and adaptive molecular insights to optimize anti-EGFR therapy.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 159 references

Cited by

See all 36

Metadata

Authors
Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C.
Affiliations
  • Universidade Federal Fluminense (BR)
  • Universidade Federal do Ceará (BR)
  • Department of Medical Sciences, Universidade Federal da Bahia, Salvador 40170-110, BA, Brazil
  • Department of Medical Sciences, Universidade Federal Fluminense, Niteroi 24220-140, RJ, Brazil
  • Centro Universitário Maurício de Nassau (BR)
  • Department of Surgery, Hospital 9 de Julho, São Paulo 01409-002, SP, Brazil
  • Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
  • BC Cancer Agency (CA)
  • Université de Sherbrooke (CA)
Corresponding author
Megid, Thais Baccili Cury
Venue
Cancers
Publisher
MDPI AG
Published
2025-08-27
Volume
17
Issue
17
Pages
2804
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4413757473
Cited by
32
References
159
Citations by year
2026: 26 · 2025: 6
FWCI
3.76
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
anti-EGFR therapy, metastatic colorectal cancer, EGFR inhibitors, acquired drug resistance, primary resistance, comprehensive molecular profiling, ERBB2 amplification, MET amplification, PI3K/Akt signaling, circulating tumor DNA, liquid biopsy, clonal evolution, precision oncology, bispecific antibodies, antibody-drug conjugates, RNA therapeutics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance. https://app.cochat.ai/papers/10.3390/cancers17172804
The paper
Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C. (2025). Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance. Cancers. https://doi.org/10.3390/cancers17172804

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.